Novartis Investigative Site

Reggio Emilia, RE 42123

1 studies enrolling now · 14 studies all time

What they study most

Asthma, Autoimmunity, Inflammation, B-cell Acute Lymphoblastic Leukemia (B-ALL), B-cell Non-Hodgkin Lymphoma (B-NHL), Breast Cancer, Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive, Colorectal Cancer, Diffuse Large B-cell Lymphoma, Giant Cell Arteritis, HR+/HER2- Ductal and Lobular Breast Cancer, Inflammatory Diseases, Newly Diagnosed and Recurrent Glioblastoma

Studies at this site

• Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers — Recruiting now
• Secukinumab Open Label Roll-over Extension Protocol — Recruiting now
• Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies — Running, not enrolling
• Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) — Completed
• A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP — Running, not enrolling
• Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma — Running, not enrolling
• Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR — Completed
• LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib — Completed
• Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC — Completed
• A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica — Stopped early
• Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors — Completed
• 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis — Completed
• Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma — Completed
• Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy — Completed